Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

FLUOXETINE

4 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis	6
17	Multiple system atrophy	1

ID	Disease name (Link within this page)	Number of trials
78	Hypopituitarism	0
86	Pulmonary arterial hypertension	2

13. Multiple sclerosis

Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

Clinical trials : 142 / Drugs : 142 - (DrugBank : 44) / Drug target genes : 59 - Drug target pathways : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

Clinical trials : 34 / Drugs : 44 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 19

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries

Clinical trials : 1,288 / Drugs : 565 - (DrugBank : 126) / Drug target genes : 81 - Drug target pathways : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries